Spyre Therapeutics Inc.

NASDAQ: SYRE · Real-Time Price · USD
17.13
0.27 (1.60%)
At close: Aug 15, 2025, 12:42 PM

Spyre Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a 886K 2.33M 18.74M
Cost of Revenue
n/a n/a n/a n/a
Gross Profit
n/a 886K 2.33M 18.74M
Operating Income
-208.57M -242.3M -84.78M -65.65M
Interest Income
21.31M 6.15M 837K 111K
Pretax Income
-207.97M -338.82M -83.95M -65.66M
Net Income
-208.02M -338.79M -83.81M -65.8M
Selling & General & Admin
45.78M 39.95M 28.53M 27.32M
Research & Development
162.79M 89.5M 58.58M 57.07M
Other Expenses
n/a 113.74M n/a n/a
Operating Expenses
208.57M 243.19M 87.11M 84.39M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
n/a 243.19M 87.11M 84.39M
Income Tax Expense
51K -26K -136K 141K
Shares Outstanding (Basic)
47.03M 6.9M 3.37M 2.63M
Shares Outstanding (Diluted)
47.03M 6.9M 3.37M 2.63M
EPS (Basic)
-0.56 -46.15 -24.86 -25.02
EPS (Diluted)
-0.56 -46.15 -24.86 -25.02
EBITDA
-207.97M -127.6M -82.82M -64.07M
EBIT
-207.97M -128.56M -84.78M -65.65M
Depreciation & Amortization
n/a 964K 1.96M 1.58M